Gossamer Bio Inc.

GOSS | NASDAQ

Price Alert Chart Builder DCF Calculator

$11.28

+$0.55 (+5.13%)

At close: Sep 21, 2026, 4:00 PM ET

$11.32

+$0.04 (+0.35%)

Pre-market: Sep 22, 2026, 4:05 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+5.13%

(1D)

Rating

Updated: Sep 12, 2026

10.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $68.93M

1D Range

10.95 11.54

52W Range

9.12 309.60

Valuation (TTM)

PE -16.11

PB -0.73

EV/EBITDA -0.25

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target $3.47

Cash Flow

FCF Yield -235.9%

SBC Adj. FCF Yield -256.7%

SBC Impact -8.8%

Margins

Gross Margin 99.6%

Operating Margin -311.7%

FCF Margin -305.2%

Growth (CAGR)

Revenue 3Y | 5Y -33.7% | 38.8%

Dil EPS 3Y | 5Y -26.2% | 45.6%

FCF 3Y | 5Y -74.2% | 5.0%

Returns

ROA -162.9%

ROE 108.8%

ROIC 670.0%

Financial Health

Net Cash

$20.88M

Current Ratio 0.53

Interest Coverage -15.16

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and on...

Sector Healthcare

Industry Biotechnology

Employees 144

IPO Date Feb 7, 2019

Website www.gossamerbio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 4, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Downside

-73.40%

Buy (4)

Hold (2)

Sell (1)

Analyst Details ➞